Respiratory Infections

A multi-prong approach reduces inappropriate antibiotic prescribing to outpatients with upper respiratory tract infection.

Clarametyx Biosciences said its investigational antibody therapy, CMTX-101, which is in a phase 1b/2a study, remains on track for full trial enrollment by the end of 2025.

In a continuing trend from the last several years, a record number of families are opting out of vaccines.

The designation is for the company’s TXA14007, its investigational antibiotic to be studied in combination with levofloxacin.

Current prevention strategies include two injectables for infants and young children, namely palivizumab and nirsevimab.

Michigan dairy worker's infection is linked to widespread H5N1 outbreaks, as new findings suggest increased transmission risk and moderate disease in mammals.

The agencies are calling for sustained investments in immunization efforts in the midst of increasing case numbers rising for diseases such as whooping cough, measles, and others.

Since its detection in early 2024, H5N1 has spread to dairy cows, poultry, and wild birds. Political factors, including leadership changes at the Centers for Disease Control and Prevention and cuts to public health resources, have worsened the situation, leading to a weakened response.

This case represents the second reported human infection with avian influenza A(H5) in Mexico, and the first confirmed case of influenza A(H5N1) in the country. The patient was a child who died from respiratory complications.

The Centers for Disease Control and Prevention (CDC) says there are now 7 outbreaks.

CDC maintains low public health risk despite more cases, the first reported death, and accelerated vaccine development to enhance pandemic preparedness.

A child who was not vaccinated succumbed to measles pulmonary failure. Additionally, increased cases and hospitalizations continue to grow greatly in the state.

Kansas now has an outbreak with at least 10 confirmed cases with an expectation from the state's health officials that there will be more.

Studies highlight the role of home visits, chest radiography, and sputum monitoring in TB prevention and treatment outcomes.

A 26% rise in childhood tuberculosis cases underscores the need for strengthened global TB control efforts.

Cases in the US continue to increase, and a new analysis shows 2024 was the highest year for measles cases in Europe in 25 years.

Texas is experiencing its largest measles outbreak in 30 years and the Centers for Disease Control and Prevention's (CDC) Epidemic Intelligence Service is providing support there. Here is an overview on testing, disease presentation, and vaccination, as well as commentary on the public health impact of vaccine hesitancy, and the unintended consequences of the immunization program’s success.

The official cause of death is still under investigation by the New Mexico Office of the Medical Investigator, though the individual tested positive for the measles virus.

Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.

New study by Gabriel Nussbaum, MD, PhD, et al, reveals how P gingivalis escapes immune detection, contributing to gum disease and increasing risks for systemic infections such as respiratory disease.

The state’s health department has confirmed all 3 cases are in people who are unvaccinated.

The CDC tracks rising human infections linked to poultry and dairy exposure, while the USDA steps up with a comprehensive strategy to combat HPAI and stabilize egg prices.

Jeff Freiberg, MD, PhD, on the rising emerging infection concerns of dengue, mpox, measles, and H5N1 influenza in clinical practice.

Two cats became severely ill, and both owners declined to be tested.

Andrew Engeli explains Ginkgo's role in the €24 million EU-Funded RANGER project for emerging infectious disease surveillance and response.

A state official says the woman is hospitalized in another state, and had preexisting health conditions that can make people more vulnerable to illness.

In the Phase 3 trial, GSK's vaccine met all 11 primary endpoints, providing expanded options for preventing invasive meningococcal disease in individuals aged 10-25 years.

Twenty-four cases have been identified within the last two weeks, and 22 of those cases are in children. Nine of the cases have required hospitalization.

Heather Platt, MD, discusses Merck’s latest achievement with Capvaxive and its potential to significantly reduce invasive pneumococcal disease and pneumonia in high-risk adult populations across Europe.

The affected person had a mild case and is recovering.